methyl (E)-3-(methoxy(phenyl)methylene)-2-oxoindoline-6-carboxylate

We are methyl (E)-3-(methoxy(phenyl)methylene)-2-oxoindoline-6-carboxylate CAS:1168150-46-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:  methyl (E)-3-(methoxy(phenyl)methylene)-2-oxoindoline-6-carboxylate
CAS.NO: 1168150-46-6
Synonyms:
3-[1-methoxy-1-phenylmeth-(E)-ylidene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid methyl ester

Molecular Formula: C18H15NO4
Molecular Weight:  309.31600

Physical and Chemical Properties:
Density:  1.3±0.1 g/cm3
Boiling point: 523.8±50.0 °C at 760 mmHg
Melting point:/
Flash point:270.6±30.1 °C
Refractive index:1.614

Specification:
Appearance:  yellow powder
Purity:≥99%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage: Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:
Intermediates of Nintedanib esylate CAS:656247-18-6
Intermediates of Nintedanib CAS:656247-17-5

Related News: With the improvement of people’s living standards and the aging degree, the demand for medicines has been increasing for a long time. Therefore, the transfer from finished medicines to bulk medicines has greatly promoted the demand for bulk medicines.Tetrahidrocloruro de 1,4,7,10-tetraazaciclododecano CAS:10045-25-7 With the improvement of people’s living standards and the aging degree, the demand for medicines has been increasing for a long time. Therefore, the transfer from finished medicines to bulk medicines has greatly promoted the demand for bulk medicines.Acetoacetanilida CAS:102-01-2 In the context of the new medicine policy, with the development of China’s R & D strength, the number of innovative drugs approved has been blown out, which further strengthened the demand and speed of industrialization of raw materials in China.84-57-1 Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country.Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country.